Sibel Health closed a $30 million equity financing and earned its seventh FDA 510(k) clearance. Existing investors, the Steele Foundation for Hope and Dräger, led the financing. The company plans to use funds to accelerate the deployment of its Anne One monitoring platform. Anne One includes advanced wearable sensors, AI-enabled data analytics, and an integrated mobile software and cloud platform. It delivers wireless monitoring for all vital signs for patients 12 years and older.
Related: Cardiac Dimensions snags $53m for mitral valve device
The Steele Foundation for Hope previously led Sibel’s Series B round in 2022 and added a new $20 million investment. Dräger, which led the company’s Series A round, contributed $10 million more in funding.
“Given the very challenging financing environment, we are ecstatic to see our existing investors fund our entire round given their confidence in our product roadmap and growth trajectory,” said Dr. Steve Xu, co-founder and CEO of Sibel Health.
The financing comes as Sibel secured 510(k) clearance that enables alarms and alerts along with a powerful central station.
“We are especially proud of the fact that our sensors are FDA-cleared under the IEEE SDC 11073 standard, which supports open and secure communication between medical devices replacing traditional proprietary networks. Interoperability is the future and our hospital partners are increasingly demanding it,” said Jong Yoon Lee, chief technology officer and co-founder of Sibel Health.
